Tessera Therapeutics
Our Gene Writing™ technology advances genetic medicine beyond its current limitations. Learn more at http://TesseraTherapeutics.com
Tessera Therapeutics
A biotech company using Gene Writing™ technology for in vivo genome engineering, targeting patients with unmet medical needs to cure diseases.
About
Needs Assessment
Active buying signals and potential business opportunities
Technology Requirements
Advanced gene editing tools and platforms
High-throughput screening technologies
Bioinformatics and data analysis software
Service Requirements
Regulatory consulting for in vivo genetic treatments
Clinical trial management and support
Expertise in gene therapy development and manufacturing
Infrastructure Requirements
Specialized laboratory equipment for genome engineering
Secure data storage and analysis infrastructure
Advanced computing resources for simulations and modeling
Talent Requirements
Experienced gene therapy scientists and engineers
Specialists in non-viral delivery technologies
Regulatory affairs professionals
AI Insights
Growth Trajectory
With investment received for sickle cell disease treatment development and a focus on in vivo programs, the company shows strong growth potential in the genetic therapy market.
Market Opportunity
The company's first-of-its-kind Gene Writing technology offers a significant market opportunity by addressing major unmet medical needs with potentially curative therapies.
Access Our Live VC Funding Database
30,000+ funded startups
tracked in the last 3 months
B2B verified emails
of key decision makers
Growth metrics
Real-time company performance data
Live updates
of new VC funding rounds
Advanced filters
for sophisticated queries
API access
with multiple export formats